Theracryf 将来の成長

Future 基準チェック /06

Theracryfの収益は年間150.1%で減少すると予測されていますが、年間利益は年間30.7%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-131.5% 55.5%なると予測されています。

主要情報

30.7%

収益成長率

55.5%

EPS成長率

Biotechs 収益成長	37.3%
収益成長率	-150.1%
将来の株主資本利益率	-131.5%
アナリストカバレッジ	Low
最終更新日	14 Jun 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Oct 11

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Nov 24

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Aug 06

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Apr 09

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Dec 25

業績と収益の成長予測

AIM:TCF - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2026	N/A	-2	-2	-2	2
3/31/2025	N/A	-1	-1	-1	2
3/31/2024	0	-3	-3	-3	N/A
12/31/2023	1	-3	-3	-3	N/A
9/30/2023	1	-3	-4	-4	N/A
6/30/2023	1	-4	-4	-4	N/A
3/31/2023	0	-4	-4	-4	N/A
12/31/2022	0	-4	-4	-4	N/A
9/30/2022	N/A	-3	-3	-3	N/A
6/30/2022	N/A	-3	-3	-3	N/A
3/31/2022	N/A	-3	-3	-3	N/A
12/31/2021	N/A	-3	-3	-3	N/A
9/30/2021	N/A	-2	-3	-3	N/A
6/30/2021	0	-3	-3	-3	N/A
3/31/2021	0	-3	-3	-3	N/A
12/31/2020	0	-3	-3	-3	N/A
9/30/2020	0	-3	-3	-3	N/A
6/30/2020	0	-3	-3	-3	N/A
3/31/2020	N/A	-3	-3	-3	N/A
12/31/2019	N/A	-3	-3	-3	N/A
9/30/2019	N/A	-2	-2	-2	N/A
6/30/2019	N/A	-3	-2	-2	N/A
3/31/2019	N/A	-3	-2	-2	N/A
12/31/2018	N/A	-3	-2	-2	N/A
9/30/2018	N/A	-3	-2	-2	N/A
6/30/2018	N/A	-3	-2	-2	N/A
3/31/2018	N/A	-3	-2	-2	N/A
12/31/2017	N/A	-3	N/A	-3	N/A
9/30/2017	N/A	-3	N/A	-3	N/A
6/30/2017	N/A	-3	N/A	-3	N/A
3/31/2017	N/A	-3	N/A	-3	N/A
12/31/2016	N/A	-3	N/A	-3	N/A
9/30/2016	N/A	-4	N/A	-3	N/A
6/30/2016	N/A	-3	N/A	-2	N/A
3/31/2016	N/A	-3	N/A	-2	N/A
12/31/2015	N/A	-3	N/A	-1	N/A
9/30/2015	N/A	-2	N/A	-1	N/A
6/30/2015	N/A	-2	N/A	-1	N/A
3/31/2015	N/A	-2	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TCF今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TCF今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: TCF今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TCF来年は収益がないと予測されています。

高い収益成長: TCF来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TCF 3 年以内に赤字になると予測されています。

Theracryf 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates fall by 92%

Consensus forecasts updated

Recent updates

Theracryf Plc Announces Demise of Sue Foden, Chair

New major risk - Share price stability

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024

New minor risk - Financial data availability

Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.

Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.

Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer

Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

New minor risk - Share price stability

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma Studies

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation Approved

New major risk - Market cap size

New minor risk - Share price stability

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Consensus revenue estimates fall by 92%

Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023

Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts Dosed

Consensus forecasts updated

Evgen Pharma plc to Report First Half, 2023 Results on Dec 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Clinical Trial Update

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Receives Regulatory and Ethical Approvals for A Healthy Volunteer, Pharmacokinetic and Pharmacodynamic, Study Toexamine the Performance of the Company's New Enteric Coated Tablet Formulation of Lead Asset SFX-01

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Evgen Pharma plc to Report Fiscal Year 2022 Results on Jun 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Progress Discussions with the UK Medicines and Healthcare Products Regulatory Agency and the US Food and Drug Administration

Insufficient new directors

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Announces Early Data for SFX-01 in Leukaemia Cell Lines

Evgen Pharma plc Announces Glioma Orphan Drug Application Submitted to US FDA

Evgen Pharma plc Announces Progress on Metastatic Breast Cancer Programme

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Evgen Pharma plc Provides Update on Data Safety Review for STAR COVID-19 Trial

Evgen Pharma plc Updates on Patient Recruitment

Evgen Pharma plc, Annual General Meeting, Mar 03, 2021

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Evgen Pharma plc to Report Fiscal Year 2020 Results on Jun 15, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘